CN100469784C - 甘油一酯和甘油二酯糖苷作为抗炎药物的用途 - Google Patents

甘油一酯和甘油二酯糖苷作为抗炎药物的用途 Download PDF

Info

Publication number
CN100469784C
CN100469784C CNB028258169A CN02825816A CN100469784C CN 100469784 C CN100469784 C CN 100469784C CN B028258169 A CNB028258169 A CN B028258169A CN 02825816 A CN02825816 A CN 02825816A CN 100469784 C CN100469784 C CN 100469784C
Authority
CN
China
Prior art keywords
purposes
acyl group
alkyl
triolefin
age
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB028258169A
Other languages
English (en)
Chinese (zh)
Other versions
CN1606563A (zh
Inventor
E·拉尔森
A·哈拉茨米
S·B·克里斯滕森
L·P·克里斯滕森
K·勃兰特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Aarhus University
Rigshospitalet
Original Assignee
Danish University Of Medicine
H S RIGSHOSPITALET
Københavns Universitet
Aarhus University
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danish University Of Medicine, H S RIGSHOSPITALET, Københavns Universitet, Aarhus University, Rigshospitalet filed Critical Danish University Of Medicine
Publication of CN1606563A publication Critical patent/CN1606563A/zh
Application granted granted Critical
Publication of CN100469784C publication Critical patent/CN100469784C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
CNB028258169A 2001-11-21 2002-11-21 甘油一酯和甘油二酯糖苷作为抗炎药物的用途 Expired - Lifetime CN100469784C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US33208401P 2001-11-21 2001-11-21
US60/332,084 2001-11-21
US34160901P 2001-12-18 2001-12-18
US60/341,609 2001-12-18
US35839102P 2002-02-22 2002-02-22
US60/358,391 2002-02-22

Publications (2)

Publication Number Publication Date
CN1606563A CN1606563A (zh) 2005-04-13
CN100469784C true CN100469784C (zh) 2009-03-18

Family

ID=27406836

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028258169A Expired - Lifetime CN100469784C (zh) 2001-11-21 2002-11-21 甘油一酯和甘油二酯糖苷作为抗炎药物的用途

Country Status (9)

Country Link
US (2) US7084122B2 (enExample)
EP (1) EP1453844B1 (enExample)
JP (2) JP4716655B2 (enExample)
CN (1) CN100469784C (enExample)
AU (1) AU2002366210A1 (enExample)
DK (1) DK1453844T3 (enExample)
NO (1) NO334587B1 (enExample)
PL (2) PL393941A1 (enExample)
WO (1) WO2003043613A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475554A (zh) * 2016-06-27 2019-03-15 俄亥俄州国家创新基金会 基于脂核苷酸的ards治疗

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004151D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004152D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
AR035700A1 (es) * 2001-05-08 2004-06-23 Astrazeneca Ab Derivados de arilheteroalquilamina, composicion farmaceutica, usos de estos derivados para la fabricacion de medicamentos, metodos de tratamiento, y proceso para la preparacion de estos derivados
SE0102640D0 (sv) * 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
SE0203304D0 (sv) * 2002-11-07 2002-11-07 Astrazeneca Ab Novel Coumpounds
JP3914519B2 (ja) * 2003-06-06 2007-05-16 株式会社スピルリナ研究所 グリセロ糖脂質化合物を含有してなるリパーゼ活性阻害剤
US7758903B2 (en) 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
KR101245440B1 (ko) * 2003-09-12 2013-03-19 액세스 비지니스 그룹 인터내셔날 엘엘씨 사이토킨 조절물질 및 관련된 용도
US7758902B2 (en) * 2003-09-12 2010-07-20 Access Business Group International Llc Cytokine modulators and related methods of use
JP3790767B2 (ja) * 2004-06-30 2006-06-28 森下仁丹株式会社 脂肪代謝改善組成物
US20070269540A1 (en) * 2006-05-16 2007-11-22 Morishita Jintan Co., Ltd. Fat metabolism improving agent
JP4866067B2 (ja) * 2005-11-22 2012-02-01 株式会社ファンケル メラニン産生抑制剤
US8435588B2 (en) 2005-11-23 2013-05-07 The Coca-Cola Company High-potency sweetener composition with an anti-inflammatory agent and compositions sweetened therewith
ATE524483T1 (de) * 2006-07-03 2011-09-15 Hyben Vital Licens Aps Verfahren zur herstellung eines glykosids eines mono- oder diacylglyzerinprodukts aus einem pflanzlichen material
US7547455B2 (en) * 2006-09-20 2009-06-16 Academia Sinica Cancer and inflammatory disorder treatment
KR100772078B1 (ko) 2006-11-07 2007-10-31 한국기초과학지원연구원 갈조류 지충이로부터 분리된 신규모노갈락토실디아실글리세롤 화합물
JPWO2008108001A1 (ja) * 2007-03-02 2010-06-10 株式会社東洋新薬 ガラクト脂質
HRP20150593T1 (hr) * 2007-12-21 2015-07-31 Finzelberg Gmbh & Co. Kg Pripravci s ekstraktima šipka i postupak proizvodnje ekstrakta šipka
NZ567712A (en) * 2008-04-24 2010-11-26 Fonterra Cooperative Group Ltd Compositions and methods for maintaining bone health or reducing bone loss
US9173912B2 (en) 2008-05-06 2015-11-03 Finzelberg Gmbh & Co. Kg Cistus extract containing enriched secondary plant ingredients
EP2349281A1 (en) 2008-10-30 2011-08-03 Hyben Vital Licens ApS Composition comprising a glycoside of a mono- or diacyiglycerol compound and an oil rich in n-3 polyunsaturated fatty acids, a method of producing the composition and use of the composition
DK177605B1 (en) 2010-03-16 2013-11-18 Hyben Vital Licens Aps Compositions of rose hips enriched with seeds of rose hips and their use as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and joint diseases such as arthritis and/or osteo-arthritis
EP2389816A1 (en) 2010-05-25 2011-11-30 Nestec S.A. Synergistic antioxidant composition
MX2012015059A (es) * 2010-06-25 2013-04-03 Horphag Res Ip Pre Ltd Composicion para mejorar el bienestar sexual.
TWI558403B (zh) * 2013-06-04 2016-11-21 中央研究院 富含半乳糖脂之植物萃取物及其用途
JP6339426B2 (ja) * 2014-06-30 2018-06-06 株式会社ファンケル グリセロ糖脂質を含有する組成物の製造方法及びグリセロ糖脂質含有組成物
CN106983763B (zh) * 2017-04-25 2021-04-20 中国海洋大学 单半乳糖基二酰基甘油酯及其制备方法与用途
CN110201026B (zh) * 2019-07-15 2021-09-24 青岛农业大学 一种非抗生素型结肠炎修复制剂
KR102780726B1 (ko) * 2022-12-30 2025-03-13 주식회사 미래생명자원 테트라셀미스 츄이로부터 분리한 신규 화합물 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336437A (ja) 1993-03-30 1994-12-06 Takeda Shokuhin Kogyo Kk 発癌プロモーション抑制組成物
JPH07149786A (ja) 1993-11-26 1995-06-13 Sagami Chem Res Center グリセロ糖脂質及び発癌プロモーター阻害剤
US5620962A (en) * 1993-04-30 1997-04-15 Winget; Rodner R. Anti-inflammatory compositions containing monogalactosyl dieicosapentaenoyl glycerol and methods of relating thereto

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05271270A (ja) 1992-03-27 1993-10-19 Nippon Paper Ind Co Ltd 糖ーグリセロール誘導体とその合成法
CA2142153A1 (en) 1994-03-04 1995-09-05 Jacques Banville Sulfated .beta.-glycolipid derivatives as cell adhesion inhibitors
US5663151A (en) * 1994-03-04 1997-09-02 Bristol-Myers Squibb Company Sulfated α-glycolipid derivatives as cell adhesion inhibitors
US5486536A (en) * 1994-08-15 1996-01-23 The Regents Of The University Of Michigan Sulfatides as anti-inflammatory compounds
DE19634021A1 (de) 1996-08-23 1998-02-26 Beiersdorf Ag Antiadhäsive Glycoglycerolipide
DE19634019A1 (de) * 1996-08-23 1998-02-26 Beiersdorf Ag Gegen Mikroogranismen, Viren, Parasiten und Protozoen wirksame Glycoglycerolipide
DE19700774A1 (de) 1997-01-13 1998-07-16 Hoechst Ag Antiadhäsive Sulfatid-Mimetika
US6024960A (en) * 1998-04-17 2000-02-15 Otto Torbjorn Hansen And Marianne Hansen Rose-hip formulations as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and arthritis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06336437A (ja) 1993-03-30 1994-12-06 Takeda Shokuhin Kogyo Kk 発癌プロモーション抑制組成物
US5620962A (en) * 1993-04-30 1997-04-15 Winget; Rodner R. Anti-inflammatory compositions containing monogalactosyl dieicosapentaenoyl glycerol and methods of relating thereto
JPH07149786A (ja) 1993-11-26 1995-06-13 Sagami Chem Res Center グリセロ糖脂質及び発癌プロモーター阻害剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109475554A (zh) * 2016-06-27 2019-03-15 俄亥俄州国家创新基金会 基于脂核苷酸的ards治疗

Also Published As

Publication number Publication date
AU2002366210A1 (en) 2003-06-10
US20050049205A1 (en) 2005-03-03
EP1453844B1 (en) 2013-11-20
US20030139350A1 (en) 2003-07-24
WO2003043613A2 (en) 2003-05-30
EP1453844A2 (en) 2004-09-08
JP2010215660A (ja) 2010-09-30
CN1606563A (zh) 2005-04-13
WO2003043613A3 (en) 2004-03-25
NO334587B1 (no) 2014-04-14
JP2005513023A (ja) 2005-05-12
US7084122B2 (en) 2006-08-01
PL213644B1 (pl) 2013-04-30
DK1453844T3 (da) 2014-02-10
NO20042112L (no) 2004-07-09
PL393941A1 (pl) 2011-06-20
JP4716655B2 (ja) 2011-07-06
AU2002366210A8 (en) 2003-06-10
PL370888A1 (en) 2005-05-30

Similar Documents

Publication Publication Date Title
JP4716655B2 (ja) 抗炎症剤としてのモノ−およびジアシルグリセロールのグリコシドの使用
Jemai et al. Lipid-lowering and antioxidant effects of hydroxytyrosol and its triacetylated derivative recovered from olive tree leaves in cholesterol-fed rats
Simões et al. Effect of Brazilian green propolis on the production of reactive oxygen species by stimulated neutrophils
JP2619491B2 (ja) アスタキサンチン含有組成物
JP3065710B2 (ja) 抗炎症剤
KR20200106169A (ko) 칸나비노이드를 포함하는 변형 방출형 조성물
Khajuria et al. Immunomodulatory effects of two sapogenins 1 and 2 isolated from Luffa cylindrica in Balb/C mice
US8809522B2 (en) Method of preparing a glycoside of a mono- or diacylglycerol product from a plant material
JP2019519556A (ja) カンナビノイド製剤
US20140031304A1 (en) Anti-cholesterolemic compounds and methods of use
Mustapha et al. Immunomodulatory potencies of isolated compounds from Crataegus azarolus through their antioxidant activities
Hidvégi et al. Effect of MSC on the immune response of mice
AU707677B2 (en) New use
US12186355B2 (en) Phytocomplex and selected extract of a meristematic cell line of a plant belonging to the genus melissa
US5260067A (en) Cytotropic heterogeneous molecular lipids (CHML) and process for preparing the same
EP0381823A2 (en) Cytotropic heterogenous molecular lipids (CHML) and process for preparing the same
Kacemi et al. Bee Pollen as a Source of Pharmaceuticals: Where Are We Now?
WO2024075835A1 (ja) ナンノクロロプシス（Ｎａｎｎｏｃｈｌｏｒｏｐｓｉｓ）属藻類の水抽出物による体重増加の抑制作用
KR20020063038A (ko) 면역증강 및 생리활성 효과를 갖는 씀바귀 추출물
KR100836941B1 (ko) 차가버섯으로부터 분리된 항산화 화합물 및 이를 포함하는 조성물
Gupta et al. Evaluation of Memory Enhancing Activity of Chloroform Extract of Plumbago zeylanica Linn. by Different Models in Rats.
KR100831757B1 (ko) 페리너스 속 버섯 또는 이노노투스 속 버섯의 균사체 배양물로부터 분리된 항산화 화합물 및 이를 포함하는 조성물
HK40123334A (en) Action for suppressing any increase in body weight by aqueous extract of nannochloropsis algae
AU2011247864B2 (en) A method of preparing a glycoside of a mono- or diacylglycerol product from a plant material
Ngmenpone ISOLATION, CHARACTERIZATION AND ANTI-INFECTIVE STUDY OF COMPOUNDS FROM THE LEAF OF ALOE BARBADENSIS MILLER

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: AARHUS UNIVERSITY; APPLICANT

Free format text: FORMER OWNER: DENMARK AGRICULTURE SCIENCE ACADEMY; APPLICANT

Effective date: 20070615

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20070615

Address after: Aarhus

Applicant after: Aarhus Universitet

Co-applicant after: RIGSHOSPITALET

Co-applicant after: University OF COPENHAGEN

Address before: Denmark tjele

Applicant before: H. S. Rigshospitalet

Co-applicant before: RIGSHOSPITALET

Co-applicant before: Danish University of Medicine

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term

Granted publication date: 20090318

CX01 Expiry of patent term